Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04907084 · ClinicalTrials.gov registry record · Phase 2
Serine and Fenofibrate Study in Patients With MacTel Type 2
A Phase 2 study of Macular Telangiectasia Type 2, sponsored by The Lowy Medical Research Institute Limited.
- Active
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 9
- Study locations
NCT04907084: Active Phase 2 study of Macular Telangiectasia Type 2, sponsored by The Lowy Medical Research Institute Limited.
NCT04907084 is a Phase 2 study of Macular Telangiectasia Type 2 that is active but no longer recruiting, run by The Lowy Medical Research Institute Limited. The registered enrollment target is 60 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower). The trial reports 9 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04907084, a Phase 2 study of Macular Telangiectasia Type 2, is active but no longer recruiting, sponsored by The Lowy Medical Research Institute Limited.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 9
- Study locations
Study Summary
This is a Phase 2a study of the effect of serine supplementation and fenofibrate treatment on serum deoxysphingolipid levels in patients with macular telangiectasia type 2 (MacTel). This study involves six arms. Participants will be randomly assigned to one of the following treatment groups: serine 200 mg/kg/day, serine 400 mg/kg/day, fenofibrate 160 mg/day, both serine 200 mg/kg/day and fenofibrate 160 mg/day, both serine 400 mg/kg/day and fenofibrate 160 mg/day, or no treatment (control group). Serum deoxysphingolipid levels will be used as the primary outcome, and safety will be evaluated. The participants will be followed for 10 weeks, with visits at Screening, Week 0, 3, 6 and 10.
Primary Outcome
Any changes in serum deoxysphingolipid levels measured (determined via serum sample) at 3 weeks, 6 weeks, and/or 10 weeks when compared with baseline levels measured in week 0
Conditions Studied
Interventions
- DRUG Fenofibrate
- DIETARY_SUPPLEMENT Serine
Study Locations (9)
Georgia
- Emory University - Atlanta
Michigan
- Kellogg Eye Center, University of Michigan - Ann Arbor
Ohio
- Retina Associates of Cleveland - Cleveland
Tennessee
- Southeastern Retina Associates - Knoxville
Texas
- Retina Consultants of Texas - Bellaire
Utah
- Moran Eye Center, University of Utah - Salt Lake City
Washington
- University of Washington - Seattle
Wisconsin
- The Eye Institute, Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2022-04-07 |
| Est. Completion | 2024-03 |
| Phase | Phase 2 |
What the registry record for NCT04907084 still lists
NCT04907084 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower).
The record links to 1 condition, with Macular Telangiectasia Type 2 appearing as the primary indexed condition, and to 2 interventions - of which Fenofibrate is the first listed.
NCT04907084 lists 9 locations in 9 states (Georgia, Michigan, Ohio).
Frequently Asked Questions
What is clinical trial NCT04907084 about?
NCT04907084 is a clinical study titled "Serine and Fenofibrate Study in Patients With MacTel Type 2". This is a Phase 2a study of the effect of serine supplementation and fenofibrate treatment on serum deoxysphingolipid levels in patients with macular telangiectasia type 2 (MacTel). This study involves six arms. Participants will be randomly assigned to one of the following treatment groups: serine ...
What is the current status of trial NCT04907084?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2022-04-07. Estimated completion is 2024-03.
What conditions does trial NCT04907084 study?
This clinical trial studies the following conditions: Macular Telangiectasia Type 2.
What interventions are being tested in trial NCT04907084?
The interventions under investigation include: Fenofibrate (DRUG), Serine (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT04907084?
This trial is sponsored by The Lowy Medical Research Institute Limited, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04907084 being conducted?
This trial has 9 study locations across Georgia, Michigan, Ohio, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Macular Telangiectasia Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04907084's enrollment target sits among peer trials
60 1027th of 2000 higher than 868 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI